Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Malignant Lymphoma

Free Subscription 20.05.2024 1 Am J Surg Pathol 5 Blood 1 Br J Dermatol 4 Br J Haematol 2 Cancer 5 Dtsch Med Wochenschr 1 Eur J Haematol 2 Int J Radiat Oncol Biol Phys 3 Leuk Lymphoma 2 Leukemia 1 Oncol Rep

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Surg Pathol

1. MARQUES-PIUBELLI ML, Lyapichev KA, Fnu A, Adrada B, et al
   The Spectrum of Non-neoplastic Changes Associated With Breast Implants: Histopathology, Imaging, and Clinical Significance.
   Am J Surg Pathol. 2024;48:e43-e64.
   PubMed         Abstract available
   
   

   
   Blood

2. MALINVERNI C, Bernardelli A, Glimelius I, Mirandola M, et al
   Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
   Blood. 2024 May 16:blood.2023023525. doi: 10.1182/blood.2023023525.
   PubMed         Abstract available
   
   
3. 
   MRD and EFS in pediatric T-lymphoblastic lymphoma.
   Blood. 2024;143:2111.
   PubMed        
   
   
4. 
   Silva A, Almeida ARM, Cachucho A, et al. Overexpression of wild-type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma. Blood. 2021;138(12):1040-1052.
   Blood. 2024;143:2108-2110.
   PubMed        
   
   
5. YUAN CT, Ma WL
   Transformed mantle cell lymphoma with additional triple-hit genotypes can be resistant to a Bruton tyrosine kinase inhibitor.
   Blood. 2024;143:2106.
   PubMed        
   
   
6. RIBERA JM
   MRD: also for T-lymphoblastic lymphoma.
   Blood. 2024;143:2017-2019.
   PubMed        
   
   

   
   Br J Dermatol

7. JAMES M, Nakamura M, Whittaker S, Morris S, et al
   Mycosis fungoides: successful re-treatment with brentuximab vedotin.
   Br J Dermatol. 2024;190:929-930.
   PubMed        
   
   

   
   Br J Haematol

8. BROCKELMANN PJ
   Considerations for anti-PD1-based first-line treatment of Hodgkin lymphoma.
   Br J Haematol. 2024 May 16. doi: 10.1111/bjh.19534.
   PubMed         Abstract available
   
   
9. SOUMERAI JD, Diefenbach CS, Jagadeesh D, Asch A, et al
   Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.
   Br J Haematol. 2024;204:1762-1770.
   PubMed         Abstract available
   
   
10. BRILLEMBOURG H, Martinez-Cibrian N, Bachiller M, Alserawan L, et al
    The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies.
    Br J Haematol. 2024;204:1649-1659.
    PubMed         Abstract available
    
    
11. FARDELLA E, Zanirato G, Magni M, Caldarelli N, et al
    Prognostic impact of pretreatment cell-free DNA concentration in newly diagnosed peripheral T-cell lymphomas.
    Br J Haematol. 2024;204:1752-1756.
    PubMed         Abstract available
    
    

    
    Cancer

12. HSU YT, Wu SJ, Kao HW, Hsiao SY, et al
    Glofitamab as a salvage treatment for B-cell lymphomas in the real world: A multicenter study in Taiwan.
    Cancer. 2024;130:1972-1981.
    PubMed         Abstract available
    
    
13. SEDETA E, Jemal A, Nisotel L, Sung H, et al
    Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt.
    Cancer. 2024 Jan 20. doi: 10.1002/cncr.35214.
    PubMed         Abstract available
    
    

    
    Dtsch Med Wochenschr

14. WEIGERT O
    [Lymphom].
    Dtsch Med Wochenschr. 2024;149:601.
    PubMed        
    
    
15. HARTMANN S, Rudelius M
    [New classifications of malignant lymphomas - What changes are relevant for practice?].
    Dtsch Med Wochenschr. 2024;149:613-620.
    PubMed         Abstract available
    
    
16. HELLMUTH JC, Koch R, Weigert O
    [Targeted therapies in the management of malignant lymphoma - is the end of conventional chemotherapy near?].
    Dtsch Med Wochenschr. 2024;149:621-629.
    PubMed         Abstract available
    
    
17. BUCKLEIN V, von Tresckow B, Subklewe M
    [T-cell recruiting immunotherapies in B-cell lymphoma - the future backbone for all therapy lines?].
    Dtsch Med Wochenschr. 2024;149:630-637.
    PubMed         Abstract available
    
    
18. ALIG S, Pott C, Chapuy B
    [Malignant lymphomas - quo vadis? - What developments await us in diagnostics and therapy?].
    Dtsch Med Wochenschr. 2024;149:638-645.
    PubMed         Abstract available
    
    

    
    Eur J Haematol

19. VELA-OJEDA J, Olivas-Bejarano AC, Montiel-Cervantes LA, Rosales-Cruz E, et al
    Soluble MIC-A, IPI, and response to treatment strongly predict survival in patients with germinal center diffuse large B cell lymphoma.
    Eur J Haematol. 2024 May 14. doi: 10.1111/ejh.14230.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

20. COOPER BT, Mayo CS, Milano MT, Olch AJ, et al
    Predictive Factors Associated With Radiation Myelopathy in Pediatric Patients With Cancer: A PENTEC Comprehensive Review.
    Int J Radiat Oncol Biol Phys. 2024;119:494-506.
    PubMed         Abstract available
    
    
21. LO AC, Ronckers C, Aznar MC, Avanzo M, et al
    Breast Hypoplasia and Decreased Lactation From Radiation Therapy in Survivors of Pediatric Malignancy: A PENTEC Comprehensive Review.
    Int J Radiat Oncol Biol Phys. 2024;119:549-559.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

22. DI M, Su CT, Cowan AJ, Gopal AK, et al
    Mitigating time toxicity in lymphoma and multiple myeloma.
    Leuk Lymphoma. 2024 May 15:1-12. doi: 10.1080/10428194.2024.2352086.
    PubMed         Abstract available
    
    
23. DESPAS F, Chaouki M, de Barros S, Bonneau B, et al
    Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure.
    Leuk Lymphoma. 2024 May 15:1-3. doi: 10.1080/10428194.2024.2353330.
    PubMed        
    
    
24. CHERIAN S, Modelevsky L, Reiner AS, Grommes C, et al
    Treatment of methotrexate-refractory primary central nervous system lymphoma (PCNSL) at Memorial Sloan Kettering Cancer Center.
    Leuk Lymphoma. 2024 May 14:1-4. doi: 10.1080/10428194.2024.2343778.
    PubMed        
    
    

    
    Leukemia

25. LIANG JH, Wu YF, Shen HR, Li Y, et al
    Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma.
    Leukemia. 2024 May 15. doi: 10.1038/s41375-024-02279.
    PubMed         Abstract available
    
    
26. WANG TP, Ahn KW, Shadman M, Kaur M, et al
    Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis.
    Leukemia. 2024 May 15. doi: 10.1038/s41375-024-02242.
    PubMed         Abstract available
    
    

    
    Oncol Rep

27. GUO Z, Wang C, Shi X, Wang Z, et al
    Advances in proteomics in diffuse large B?cell lymphoma (Review).
    Oncol Rep. 2024;51:87.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.